Editor’s note: This is the second article in a three-part series discussing the next generation of COVID-19 testing. Read part one: “Say Hello to the TaqPath™ COVID-19 RNase P Combo Kit 2.0“. Read part three: “Say Hello to the TaqPath™ COVID-19 Fast PCR Combo Kit 2.0“.
The Applied Biosystems TaqPath™ COVID-19 RNase P Combo Kit 2.0 is a multiplexed, highly sensitive, RT‐PCR assay for the qualitative detection of SARS-CoV-2 RNA supporting nasopharyngeal and nasal swabs. The TaqPath™ COVID-19 RNase P Combo Kit 2.0 can detect the SARS-CoV-2 virus in symptomatic (CE-IVD and EUA kits) and asymptomatic (EUA kit only) individuals.
Thermo Fisher Scientific developed the TaqPath™ COVID-19 RNase P Combo Kit 2.0 considering existing and new emerging variants. The TaqPath™ COVID-19 RNase P Combo Kit 2.0 uses a new advanced assay design to compensate for emerging variants and mutations. The human RNase P assay run in the same well helps assess sample quality, indicates the presence of human nucleic acid, and serves as an internal process control.
Diagnostic testing and screening for symptomatic or asymptomatic (EUA kit only) cases
The Applied Biosystems TaqPath™ COVID-19 RNase P Combo Kit 2.0 contains assays and controls for a real-time reverse transcription polymerase chain reaction test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasopharyngeal swabs and anterior or mid-turbinate nasal swabs from individuals suspected of COVID-19 by their health care provider, as well as individuals without symptoms or other epidemiological reasons to suspect COVID-19 (EUA kit only).
An advanced assay design compensates for known and emerging SARS-CoV-2 mutations
Our innovative, multi-target assay design compensates for emerging SARS-CoV-2 mutations to provide more confidence in your results.
Sensitive detection of SARS-CoV-2
Assay sensitivity has been improved with an LoD of 75 GCE/mL, as compared to 250 GCE/mL for the TaqPath™ COVID-19 Multiplex Diagnostic Solution.
Simplified workflow and improved internal specimen control.
The TaqPath™ COVID-19 2.0 kits utilize the RNase P gene as an internal specimen control, omitting the external addition of an extraction and process control. The RNase P gene supports adequate sample sufficiency and quality for each specimen.
Simplified storage
Conveniently store all the components at –20°C, as opposed to the previous generation of COVID-19 kits which require certain components to be stored at –70°C.
Includes Applied Biosystems Pathogen Interpretive Software
The Applied Biosystems Pathogen Interpretive Software automatically validates each run and prepares a report for all tested specimens, decreasing analysis and interpretation time and helping reduce the risk of user interpretation error.
The TaqPath™ COVID-19 RNase P Combo Kit 2.0 utilizes a standard workflow that provides results in ~3 hours sample to result using our recommended sample preparation.
To learn more about the new TaqPathTM COVID-19 2.0 Assays, click here.
For more information about the TaqPath™ COVID-19 RNase P Combo Kit 2.0 performance and how to order it, click here.
Intended use and regulatory statements of products vary. For specific intended use and regulatory statements, please refer to the Instructions for Use (IFU). Product availability by country varies.